Contineum Therapeutics (CTNM) to Release Earnings on Thursday

Contineum Therapeutics (NASDAQ:CTNM) is anticipated to release its Q1 2025 earnings data before the market opens on Thursday, May 15th. Analysts expect Contineum Therapeutics to post earnings of ($0.56) per share for the quarter.

Contineum Therapeutics Price Performance

CTNM stock opened at $3.83 on Tuesday. Contineum Therapeutics has a 1-year low of $3.64 and a 1-year high of $22.00. The business has a 50-day moving average price of $5.55 and a 200 day moving average price of $10.24. The company has a market capitalization of $99.09 million and a P/E ratio of -0.78.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on CTNM shares. Jones Trading started coverage on shares of Contineum Therapeutics in a research note on Thursday, March 13th. They set a “buy” rating and a $23.00 price objective on the stock. Robert W. Baird cut their price target on Contineum Therapeutics from $32.00 to $16.00 and set an “outperform” rating on the stock in a report on Friday, March 7th. Finally, Morgan Stanley restated an “overweight” rating and set a $25.00 price objective on shares of Contineum Therapeutics in a research note on Friday, March 7th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $23.75.

Contineum Therapeutics Company Profile

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).